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Contrast-enhanced magnetic resonance imaging (MRI) was used to monitor the response of patients undergoing neoadjuvant
chemotherapy for breast cancer with the aim of undergoing breast-conserving surgery (BCS). Patients were prospectively recruited
to undergo MRI as well as conventional methods of clinical examination, mammography (MM) and ultrasonography (USS) and
response was assessed by each of these methods. Thirty-two patients with primary breast cancer were recruited. Magnetic resonance
imaging correlation with histopathological size (r¼0.71) was superior to USS (r¼0.65) and to MM where tumour size was not
measurable following chemotherapy in 71% of patients. Magnetic resonance imaging had 87.5% sensitivity (95% CI¼68–97%) and
50% specificity (95% CI¼16–84%) for a PPV (positive predictive value) of 99.8% and NPV (negative predictive value) of 80% for the
detection of residual invasive cancer. Magnetic resonance imaging displayed 80% sensitivity (95% CI¼28.4–99.5%) and 89%
specificity (95% CI¼71–98%) to detect pathological pCR in the breast. Eighty-four per cent of recruited patients were identified as
potentially suitable candidates for BCS following chemotherapy and of those choosing to accept BCS, breast conservation was
achieved in 90.5%, or 65.6% of all patients. Of those who proceeded to BCS, 9.5% required a re-do mastectomy because of positive
margins; however, no residual tumour was found on histological examination of mastectomy specimens. Magnetic resonance imaging
appears to be superior to conventional methods for assessing pathological response and the low rate of re-operation for positive
margins indicates a valuable role in aiding the decision to undergo BCS or mastectomy.
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Pre-operative neoadjuvant chemotherapy has been an important
development in the management of patients with early breast cancer.
Although no more effective than post-operative treatment in
improving survival, it has been shown to downstage large operable
tumours, and increase the proportion of women who can be offered
breast-conserving surgery (BCS), where previously a mastectomy
would have been required (Hortobagyi et al,1 9 8 3 ) .N e o a d j u v a n t
therapy also identifies the proportion of women achieving a
complete pathological remission who are likely to have an excellent
prognosis, and conversely, those for whom further treatment may be
necessary (Feldman et al, 1986; Singletary et al, 2002).
Following neoadjuvant chemotherapy, accurate assessment of
tumour size and location is necessary for planning the surgical
management of the patient. There is a poor correlation between the
histological appearances of the tumour and measurements
obtained by physical examination, mammography (MM) or
ultrasonography (USS). Radiological assessment is least accurate
in younger women who most often desire BCS because their breast
tissue is more dense making it more difficult to distinguish
invasive cancer from residual in situ carcinoma and chemother-
apy-induced fibrosis (Cocconi et al, 1984; Segel et al, 1988,
Vinnicombe, 1996).
Limitations in tumour localisation may lead to a greater
incidence of positive resection margins and the need for repeated
excision or mastectomy in patients with a consequent failure to
attain the desired goals of aesthetic breast conservation and
optimum tumour control.
It has been suggested that breast magnetic resonance imaging
(MRI) is more accurate in the diagnosis of primary breast cancer
(Cocconi et al, 1984; Gilles et al, 1994; Abraham et al, 1996; Drew
et al, 1999) and we therefore, wished to assess its use in the
evaluation of tumour response and residual tumour size following
chemotherapy when compared with conventional imaging. More
accurate information may enable appropriate planning of surgery
including BCS, minimising re-excision rates while maintaining the
efficacy and possibility of cure.
Aims
This study was designed to assess the usefulness of MRI in
measuring response to neoadjuvant chemotherapy and maximis-
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sing the successful use of BCS. Magnetic resonance imaging was
compared with MM and USS to assess its ability to predict residual
tumour size and viability. Breast surgery outcomes were recorded
and the histopathological report was used as the gold standard.
MATERIALS AND METHODS
Inclusion criteria
Patients with histologically confirmed invasive breast cancer by
core needle biopsy were prospectively recruited to the study if they
had operable breast cancer and wished to have BCS but were
judged likely to benefit from pre-operative chemotherapy to
downstage the tumour. Neoadjuvant chemotherapy was offered if
there were features thought to predict for a higher risk of
recurrence, following breast conservation, or likely failure to
achieve aesthetic breast conservation; these features included the
following: (a) tumours 4cm or greater in maximum diameter, (b)
relatively large tumours in women those have small breasts (c)
clinical nodal involvement confirmed by fine-needle aspiration.
Exclusion criteria
Patients with locally advanced breast carcinoma and inflammatory
breast cancers were excluded. All patients were assessed by chest
X-ray, bone scan and liver USS and were excluded if these were
positive for metastatic spread.
Treatment
Patients received anthracycline-based neoadjuvant chemotherapy
for six cycles at 21-day intervals with doxorubicin (60mgm
 2)o r
epirubicin (90mgm
 2) and cyclophosphamide (600mgm
 2).
Assessment
All patients had a regular clinical examination with each cycle of
treatment, and maximum tumour diameters in two perpendicular
directions were measured clinically at each visit. Patients who
failed to respond after two cycles, or, who progressed clinically
while receiving chemotherapy and received alternative chemother-
apy and salvage mastectomy, were excluded from the imaging
analysis, as imaging was incomplete. Triple breast imaging, with
MM, USS and MRI, was performed within the 4 weeks before
commencing chemotherapy and at 4 weeks after the sixth course of
chemotherapy was completed.
Mammograms were obtained on standard mammographic units
(full field digital Lorad Selenia). Mediolateral, oblique and
craniocaudal views were obtained with magnification views of
any microcalcification as necessary. The size of any mass was
measured in two perpendicular directions and an assessment made
of overall shape and border characteristic of the mass.
Examinations assessed by USS were carried out pre- and post-
treatment with high-frequency linear phased probes, centre fre-
quency 12mHz, (Acuson Sequoia) and again maximum diameters
of any masses were recorded. Volumes were not calculated
routinely. Care was taken to ensure that measurements were in
similar planes and orientations at both ultrasound and MM.
Breast MRI was carried out on a 1.5T GE Signa magnet using a
dedicated double breast coil. Axial and sagittal T1-weighted spin
echo sequences were followed by a semi-dynamic 3D T1-weighted
gradient echo sequence pre- and post-intravenous gadolinium-
DTPA (16mmolkg
 1). Morphology (shape, border characteristics)
and size of any mass was recorded by one observer, blinded to the
results of MM and USS. Time–intensity curves were routinely
plotted and characterised. The MR slice thickness, on the dynamic
and high-resolution post-contrast scans, was 2–3mm. The interval
between conventional imaging and breast MRI was under 2 weeks.
On the basis of the physical and radiological examination after
chemotherapy, and patient choice, the patients were advised by the
multi-disciplinary team to proceed to simple mastectomy or
breast-conserving segmental mastectomy and axillary dissection.
Pathological size and the composition of any residual mass at
outcome surgery was compared with the maximum tumour
diameters observed with imaging, using the Pearson’s correlation
coefficient.
RESULTS
Baseline characteristics
A total of 32 patients aged between 24 and 60 (median age 42
years) satisfied all inclusion criteria for the imaging study. Twenty-
two (69%) were pre-menopausal and 10 (31%) were peri- or post-
menopausal. Patients presented with Stage 1 (6%), Stage 2 (62%)
and Stage 3 (31%) disease and median tumour size at presentation
was 4.75cm (range¼2–8cm). Tumours were staged using the
TNM classification (Singletary et al, 2002). All completed six cycles
of anthracycline-based chemotherapy.
Response to chemotherapy
All 32 patients had MRI scans preceding neoadjuvant chemother-
apy and at the completion of chemotherapy. Twenty-eight patients
had mammograms and 30 had ultrasound scans pre- and post-
chemotherapy. Pre- and post-chemotherapy measurements, for
each imaging modality, are shown for each patient (Table 1).
Response was assessed radiologically by RECIST criteria (Therasse
et al, 2000) and clinical response, based on bi-dimensional
measurement (Table 2). Mammography data were incomplete as
it was not possible to measure the size of tumour after
chemotherapy in 18 patients (56%) because the tumour margins
were no longer assessable.
Correlation with histology
The pathological complete response rate (pCR) in the breast in this
study was 12.5%. Seven patients had a complete radiological
response as assessed by MRI. Pathological complete response was
present in four of these patients and residual foci of invasive disease
seen in the remaining three patients measuring from 0.1 to 0.6cm in
diameter. Histological size and the size assessed by USS in these
patients is shown (Table 3). It was therefore possible to detect pCR
using MRI; however, MRI overestimated the rate of pCR.
The performance of the MRI scan in detecting residual invasive
cancer was sensitivity 87.5% (95% CI¼67.6–97.3%), specificity
50% (95% CI¼15.7–84.2%) for a positive predictive value (PPV)
of 99.8% and a negative predictive value (NPV) of 80%. For the
detection of pCR the MRI scan performance was sensitivity 80%
(95% CI¼28.4–99.5%), specificity 89% (95% CI¼70.8–97.6%)
for a PPV of 56% and an NPV of 96%.
In four patients, the post-chemotherapy MRI residual tumour
size was over 1cm larger than pathological size. In each of these
cases, histological evaluation revealed the presence of DCIS, which
had an enhancement pattern on MRI that could not be
differentiated from the invasive component (Table 3).
Overall, MRI correlation with histopathological size (r¼0.71)
was superior to USS correlation (r¼0.65). Correlation could not
be obtained for MM, as tumour size was not measurable in more
than 50% of patients following chemotherapy.
Surgical outcome
Following neoadjuvant chemotherapy, 27 (84%) patients were
judged potentially suitable for BCS, on the basis of clinical
examination and radiological assessment. Of these, 21 proceeded
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sto breast conservation and 4 patients changed their mind and
chose to have mastectomy. Two patients who had no evidence of
residual tumour on physical examination or radiological assess-
ment underwent localisation biopsy and were therefore offered
radiotherapy alone; however, localisation biopsy confirmed the
absence of tumour.
Of the 21 patients who had BCS, 2 patients (10%) required
subsequent mastectomy because of positive excision margins
following the initial surgery. In one of these patients, the post-
chemotherapy pre-operative MRI showed a partial response with a
3.6 by 2.7cm area of gradual enhancement postero-lateral to the
nipple thought likely to represent residual invasive disease whereas
MM was normal and the USS showed a 0.3cm hypoechoic lesion.
Histology of the initial segmental mastectomy showed a 0.1-cm
invasive tumour involving the margin and the patient proceeded to
mastectomy, the histology of which showed no residual tumour. In
the second patient, the MRI scan reported a partial response with
an enhancing focus measuring 1.0 by 0.7cm with no discernible
tumour mass; the surrounding parenchyma displayed non-
malignant enhancement, possibly due to chemotherapy-induced
fibrosis or a residual intraduct component. In this patient, USS had
shown a 1.7-cm mass. Histology of the segmental mastectomy
showed a multifocal grade 2 infiltrating ductal carcinoma
measuring 1.8cm with associated low-grade cribriform DCIS with
a tumour deposit in the medial en face surface. Histology from the
mastectomy however showed no residual invasive cancer.
Nine patients had a mastectomy within this study. The reasons
for proceeding to mastectomy are given and include patient’s
choice, position of residual tumour and identification of residual
multifocal tumour (Table 4).
In the three patients, who chose to have mastectomy, one had a
complete response on MRI and histology and one had a small
1.5cm tumour as predicted on MRI. However, in one patient, the
post-chemotherapy tumour size on MRI was 5.6cm preoperatively
whereas the histology showed a 1.8-cm Grade 2 ductal carcinoma.
In this patient, the MRI scan had not distinguished invasive
tumour from the extensive DCIS seen on the histopathological
specimen.
It was not possible to calculate the sensitivity and specificity of
the MRI in predicting successful BCS as the MRI result was used to
guide the decision; thus, no patients were considered for BCS in
whom MRI was not thought to be favourable. This was further
confounded by two patients who did not have surgery, and three
patients who despite a favourable MRI result chose to have
mastectomy.
Table 1 Clinical features: sizes of tumours pre-chemotherapy, post-chemotherapy and after surgery
Max diameter pre-chemo (cm) Max diameter post-chemo (cm)
Age (years) Stage Clinical MRI Mammo USS MRI Mammo USS Surgery Histology (cm)
1 24 T2N0 5 4.5 NA 4.5 3 Not measurable 2.5 BCS 2.5
2 41 T3N0 6 3 3.5 2.8 2.5 3.5 2 BCS 2.3
3 52 T2N0 4 3.5 3 3.1 3.4 Not measurable 2.5 BCS 4
4 48 T2N0 4 3.5 NA 3 0 Not measurable 2 BCS 0.6
5 41 T3N1 5 4.5 2 4 1.8 1.5 1.7 BCS then re-do 1.8
6 55 T3N1 6 5 5 NA 5.6 Not measurable 3.9 Mastectomy 1.8
7 42 T2N0 5 4 5 NA 0 0 0.3 BCS then re-do 0.1
8 43 T2N0 4 2.3 5 5 2 Not measurable 1.5 BCS 1.5
9 42 T2N1 5 2.7 NA 2.2 3 Not measurable 2.2 BCS 1.4
10 40 T2N0 3 2 NA 2.3 1.3 1.8 0.8 BCS 1.3
11 49 T1N1 2 2 NA 0.6 0 0.6 0.5 Mastectomy 0
12 56 T2N2 3 2.3 2 2 1.3 Not measurable 1 BCS 0.95
13 35 T2N1 4.5 6 2 4 1.4 Not measurable 0.8 Mastectomy 4
14 49 T2N1 3 3 3 2.8 2 Not measurable 2.5 BCS 0 (DCIS)
15 55 T3N1 6 2 6 3 0 0 0 BCS 0
16 47 T2N1 5 2.3 NA NA 0 0 0.3 Radiotherapy only 0
17 60 T2N1 3 2.5 2.5 2.5 0 1 0 Radiotherapy only 0
18 36 T2N0 4 2.4 0 1.2 2.5 Not measurable 2.8 BCS 2.4
19 50 T2NX 2 2.2 1 2.1 0 0 0 BCS 0.6
20 40 T2N1 2 3 2 2.5 1.5 Not measurable 1.3 Mastectomy 1.1
21 35 T3N1 6 4.5 3 4 1.5 Not measurable 1.2 BCS 1.4
22 55 T3N1 5 5 NA 4 3 4 3.3 Mastectomy 6.7
23 33 T2N0 3.5 4 NA 3.7 1 0 0 BCS 0.1
24 37 T3N0 8 3.5 4 3 2 Not measurable 1.9 BCS 2.7
25 35 T1N0 2 2.8 2 2 1.2 Not measurable NA Mastectomy 1.5
26 47 T3N1 4 5 4 3.9 2.5 Not measurable 1.3 BCS 1.5
27 53 T3N1 6 4 3 2 1.3 0 0 Mastectomy 0.1
28 33 T2N0 2 3.5 NA 3 0.9 0 0.7 BCS 1.2
29 33 T3N1 6 4 5.5 5.2 2.5 Not measurable 2.8 BCS 4
30 25 T3N0 5 4 5.5 5 4 2 2.6 BCS 3.5
31 31 T3N1 5 4 NA 4.5 1 Not measurable 1.1 Mastectomy 1.9
32 45 T2N0 5 3 NA 3.7 2.5 Not measurable 0.4 Mastectomy 2.8
Table 2 Response to chemotherapy as measured clinically, by MRI,
mammography and ultrasound, as assessed by RECIST criteria
Response Clinical MRI MM USS
Complete response (CR) 4 (12.5%) 7 (22%) 5 (16%) 5 (16%)
Partial response (PR) 26 (81%) 17 (53%) 1 (3%) 17 (53%)
Stable disease (SD) 2 (6%) 8 (25%) 2 (6%) 4 (12.5%)
Progressive disease (PD) 0 0 0 0
Not measurable 0 0 20 (62.5%) 4 (12.5%)
n¼32 patients.
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sDISCUSSION
The use of breast MRI scanning in this group of women being
considered for BCS after neoadjuvant chemotherapy led to a more
accurate preoperative assessment of the response than MM or
ultrasound. Magnetic resonance imaging detection of residual
invasive disease in comparison with operative histology had a PPV
of 99.8% and an NPV of 80%. However, as might be expected MRI
did not perform as well in detecting complete pathological
remissions with a PPV of 56% though the NPV was 96%.
The MRI correlation with histopathological size (r¼0.71) is
similar to that found previously with correlations of r¼0.75
(Rosen et al, 2003) and 0.72 (Martincich et al, 2004) reported.
Other groups have reported correlations of r¼0.6 (Partridge et al,
2002) and r¼0.982 (Cheung et al, 2003).
Magnetic resonance imaging was superior to ultrasound for
assessment of tumour size (r¼0.61) and to physical examination.
Mammography was found to be unreliable in the assessment of
preoperative tumour size because of the inability to define the
tumour margins.
All patients were fully informed about their treatment options
and were supported by a breast care nurse so that they could
participate in the decisions about their treatment. As a result of
our policy of neoadjuvant chemotherapy (that excluded all T4
tumours) BCS was achieved in 19 out of 32 (59.4%) patients for
whom mastectomy would have otherwise been necessary. Mas-
tectomy was still required in eight (25%) patients to achieve
optimum local tumour control. The remaining five patients
(15.6%) were rendered suitable for BCS but chose mastectomy
(three patients),or radiotherapy only (two patients).
Breast MRI has been found to be very sensitive for the detection
of primary invasive breast cancer but less is known about the
accuracy of MRI for detecting residual disease after chemotherapy
as cytotoxic agents may affect the dynamics of contrast uptake
(Gilles et al, 1994; Orel et al, 1995; Hunt et al, 1996; Fisher et al,
1998; Partridge et al, 2002; Bedrosian et al, 2003).
In breast conservation, positive margins are associated with an
increased long-term risk of cancer recurrence in the ipsilateral
breast (Fourquet et al, 1989; Anscher et al, 1993; Pittinger et al,
1994; Dewar et al, 1995; Gage et al, 1996; Wazer et al, 1998;
Freedman et al, 1999; Cowen et al, 2000) and, therefore, patients
with positive margins, following BCS, require further surgery. In
our series, the re-operation rate was 9.5% (two patients) but no
histological evidence of residual tumour was found on the
mastectomy specimen.
Accurate assessment of tumour response to chemotherapy may
correctly identify which patients are suitable candidates for BCS,
minimising the rates of re-excision surgery, thereby minimising
risk and distress to the patient caused by repeated surgical
procedures. Physical examination and conventional imaging are
unable to reliably predict the presence or extent of residual or
recurrent disease.
Several studies have suggested that MRI is a more accurate
method of delineating residual tumour following neoadjuvant
chemotherapy than clinical, ultrasound or mammographic assess-
ment (Boetes et al, 1995; Abraham et al, 1996; Drew et al, 1999,
2001; Fischer et al, 1999; Balu-Maestro et al, 2002; Rieber et al,
2002; Cheung et al, 2003; Rosen et al, 2003; Martincich et al, 2004;
Warren et al, 2004). Chemotherapy-induced fibrosis has been
shown to impair the evaluation of tumour by conventional
radiological methods and physical examination (Cocconi et al,
1984; Segel et al, 1988). We also found that similar factors together
with the presence of extensive DCIS limited to the interpretation of
the MRI scans.
The final decision to undertake BCS is a complex mixture of
surgical judgement and patient’s expectations and desires, so we
were not able to assess in this study how much it had been
advanced by MRI scanning. The low rate of re operation for
positive margins (2 out of 21 9.52%) may be one measure of
success and compares favourably with other reported series
however longer term follow-up will be necessary to assess local
recurrence rates and overall survival.
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